[pubmed] Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
Posté : 05 oct. 2020 12:00
Front Neurol. 2020 Sep 11;11:1053. doi: 10.3389/fneur.2020.01053. eCollection 2020.
ABSTRACT
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
PMID:33013676 | PMC:PMC7516054 | DOI:10.3389/fneur.2020.01053
Source: https://pubmed.ncbi.nlm.nih.gov/3301367 ... 1&v=2.12.3